An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutations—mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to medicine and other factors.
[More]
Regenerative medicine is a new, exciting field that is based upon the belief that the human body has the inherent power to heal itself, but in some instances it just needs a little help.
[More]
Researchers have discovered two gene variants that raise the risk of the pediatric cancer neuroblastoma. Using automated technology to perform genome-wide association studies on DNA from thousands of subjects, the study broadens understanding of how gene changes may make a child susceptible to this early childhood cancer, as well as causing a tumor to progress.
[More]
Kensey Nash Corporation today announced that the Company has entered into a settlement agreement with St. Jude Medical which resolves all disputes between the two companies relating to the Angio-Seal vascular closure device licenses, as well as other related claims.
[More]
IMRIS Inc. today officially launched VISIUS Surgical Theatre, its new global product branding at the Congress of Neurological Surgeons (CNS) being held in Washington DC.
[More]
Kensey Nash Corporation, a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its fourth quarter and fiscal year ended June 30, 2011.
[More]
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
[More]
Kensey Nash Corporation, a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its third quarter ended March 31, 2011.
[More]
Results of two major clinical studies presented at ACC.11 - the 60th Annual Scientific Session & Expo of the American College of Cardiology - demonstrate that the Resolute drug-eluting stent from Medtronic, Inc., provides a positive and persistent treatment effect for a wide variety of patients with coronary artery disease.
[More]
AccessClosure, Inc., the U.S. market segment leader in extravascular closure devices, announced today results from the first published study (Journal of NeuroInterventional Surgery) comparing the pain associated with deployment of different vascular closure devices (VCD) as the primary endpoint.
[More]
Stephen Amidon, a novelist and co-author of The Sublime Engine: A Biography of the Human Heart, writes about the story of the human heart through the world of science, history, culture and our bodies with his brother Thomas who is a practicing cardiologist in Montana and a former medical director of The Hope Heart Institute. Thomas said, “Ironically, I did an angiogram on a patient last week who had very calcified and hardened arteries that were almost precisely in the shape of the Valentine heart… But I don't think the early depicters of that heart shape had access to the same view of the heart that I have.”
[More]
Avantra Biosciences today announced the selection of TGen Drug Development as a key test site for Avantra's new biomarker quantitation platform.
[More]
Avantra® Biosciences, a leading innovator in protein diagnostics, announced today their first shipments of the new Q400 Biomarker Workstation and the innovative Angio Qx™ BioChip Immunoassay.
[More]
Pediatric cancer researchers have identified variations in a gene as important contributors to neuroblastoma, the most common solid cancer of early childhood. The study team, led by researchers at The Children's Hospital of Philadelphia, found that common variants in the LMO1 gene increase the risk of developing an aggressive form of neuroblastoma, and also mark the gene for continuing to drive the cancer's progression once it forms.
[More]
Kensey Nash Corporation , a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its first quarter ended September 30, 2010.
[More]
St. Jude Medical, Inc., a global medical device company, today announced subset data results for the Angio-Seal™ Evolution™ Vascular Closure Device Registry. The results reaffirm the excellent sealing performance of the Angio-Seal Evolution vascular closure device in patients undergoing routine diagnostic and interventional cardiac catheterization procedures.
[More]
Vascular Solutions, Inc. and Shepherd Scientific, Inc. today announced they have entered into a distribution agreement providing for Vascular Solutions to distribute Shepherd Scientific's Angio Assist and Teirstein Edge products in the United States. The Angio Assist is an easy-to-use docking station that facilitates the introduction of guide wires into interventional devices including catheters and atherectomy burrs.
[More]
Image-guided interventions are revolutionizing cancer diagnosis and treatment. MSKCC's new Center for Image-Guided Intervention (CIGI), which opened in June, offers cancer patients the most advanced, minimally invasive diagnostic and treatment options in a unique multidisciplinary setting designed to foster rapid innovations in cancer care.
[More]
Whether it's called a hybrid room or an interventional platform, Room 9 at Stanford Hospital & Clinics is that singular space where a patient can stay in one place to be diagnosed and treated, either with surgery or the latest interventional procedure, in an environment as sterile as an operating room, with all-important imaging devices, microscopes and monitors right at hand.
[More]
Kensey Nash Corporation, a regenerative medicine company, today announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. The agreement provides for Kensey Nash to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal Vascular Closure Device, the leading arterial puncture closure product in the world.
[More]